Mezgebe Berhe
Expertise in
7
conditions

Dr. Mezgebe Berhe

Infectious Disease
North Texas Infectious Diseases Consultants, P.A.
9301 North Central Expressway, Suite 310, 
Dallas, TX 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
7
conditions
North Texas Infectious Diseases Consultants, P.A.
9301 North Central Expressway, Suite 310, 
Dallas, TX 

Overview

Dr. Berhe joined North Texas Infectious Diseases Consultants (NTIDC) in August 2005 after completing his Infectious Disease fellowship training at Virginia Commonwealth University in Richmond, VA, and his Internal Medicine residency at St Barnabas Hospital, which is affiliated with Cornell Medical Center in New York City. He also holds a Masters of Public Health Degree from VCU in Epidemiology. Since joining NTIDC in 2005, Dr. Berhe has been active in research as a primary investigator and sub-investigator for clinical trials. He also has extensive training in both tropical medicine and transplant infections.

Dr. Berhe is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Osteomyelitis, HIV/AIDS, Osteomyelitis in Children, and Myelitis.

Dr. Berhe is board certified in Infectious Disease- American Board Of Internal Medicine, Infectious Disease- American Board Of Internal Med/Infectious Disease, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 6 clinical trials. Dr. Berhe is currently accepting new patients.

Specialties

Infectious Disease

Licenses

Specialist in TX

Board Certifications

Infectious Disease- American Board Of Internal Medicine
Infectious Disease- American Board Of Internal Med/Infectious Disease
Internal Medicine- American Board Of Internal Med
Internal Medicine- American Board Of Internal Medicine

Fellowships

Infectious Disease, Medical College of Virginia Hospitals - 2005
Infectious Diseases, Medical College of Virginia - 2005

Hospital Affiliations

Baylor Scott & White Heart & Vascular Hospital - Dallas
Baylor University Medical Center
Baylor Scott & White The Heart Hospital - Dallas
Baylor Scott & White Institute For Rehabilitation - Dallas
Baylor Scott & White The Heart Hospital - Plano
Baylor Scott & White Medical Center - Uptown
Baylor University Medical Center, Part Of Baylor Scott & White Health
Baylor Scott & White The Heart Hospital - Denton

Languages Spoken

English
German
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Primewell Health Services
  • HMO
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • POS
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

North Texas Infectious Diseases Consultants, P.A.
9301 North Central Expressway, Suite 310, Dallas, TX 75231
Other Locations
North Texas Infectious Diseases Consultants, P.A.
3409 Worth Street, Suite 710, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3 Study of the Safety of Trogarzo® Administered as an Undiluted IV Push Over a Reduced Interval or as an Intramuscular Injection in Clinically Stable HIV-1 Infected Trogarzo® Experienced Patients and Healthy HIV-uninfected Volunteers
A Phase 3 Study of the Safety of Trogarzo® Administered as an Undiluted IV Push Over a Reduced Interval or as an Intramuscular Injection in Clinically Stable HIV-1 Infected Trogarzo® Experienced Patients and Healthy HIV-uninfected Volunteers
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Ibalizumab-uiyk
Study Phase: Phase 3
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drugs: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Enrollment Status: Completed
Publish Date: October 21, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
A Phase Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Pharmacokinetics, and Antiretroviral Activity of IVTMB-365 in HIV-1 Infected Participants
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Biological
Study Drug: TMB-365
Study Phase: Phase 1
View 5 Less Clinical Trials

21 Total Publications

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Journal: Annals of internal medicine
Published: December 22, 2025
Similar Doctors
Expertise in
36
conditions
Dr. Cedric W. Spak
Infectious Disease
Expertise in
36
conditions
Dr. Cedric W. Spak
Infectious Disease
Referral may be required
Before you request

Cedric Spak, M.D., PA

3410 Worth Street,, Suite #780, 
Dallas, TX 
 (6.0 miles away)
214-716-0662
Languages Spoken:
English, German, Polish, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Cedric Spak is an Infectious Disease provider practicing medicine in Dallas, Texas. Dr. Spak is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Actinomycosis, Cytomegalic Inclusion Disease, Osteomyelitis, and Cytomegalovirus Infection. Dr. Spak is board certified in Infectious Disease- American Board Of Internal Medicine, Infectious Disease- American Board Of Internal Med/Infectious Disease, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. Dr. Spak is currently accepting new patients.

Expertise in
4
conditions
Dr. Amneris E. Luque
Infectious Disease
Expertise in
4
conditions
Dr. Amneris E. Luque
Infectious Disease
Referral may be required

Dallas County Hospital District

5200 Harry Hines Blvd, 
Dallas, TX 
 (5.7 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances

Amneris Luque is an Infectious Disease provider practicing medicine in Dallas, Texas. Dr. Luque is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

Expertise in
6
conditions
Dr. Ellen E. Kitchell
Infectious Disease
Expertise in
6
conditions
Dr. Ellen E. Kitchell
Infectious Disease
Referral may be required

Dallas County Hospital District

5200 Harry Hines Blvd, 
Dallas, TX 
 (5.7 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ellen Kitchell is an Infectious Disease provider practicing medicine in Dallas, Texas. Dr. Kitchell is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex.

Frequently Asked Questions about Dr. Mezgebe Berhe

How do I make an appointment with Dr. Mezgebe Berhe?

You can book an appointment with Dr. Mezgebe Berhe by calling their office at 214-890-1616. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mezgebe Berhe a top-rated expert for Osteomyelitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mezgebe Berhe is classified as an Distinguished expert for Osteomyelitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mezgebe Berhe specialize in?

While Dr. Mezgebe Berhe is a Infectious Disease, they have specific expertise in Osteomyelitis, HIV/AIDS, and Osteomyelitis in Children. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Mezgebe Berhe participate in research or clinical trials?

Yes. Dr. Mezgebe Berhe has published 21 articles and abstracts on conditions like Osteomyelitis. You can view a list of Dr. Mezgebe Berhe's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mezgebe Berhe accept my insurance?

Dr. Mezgebe Berhe accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 214-890-1616 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Berhe's expertise for a condition
ConditionClose
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile